Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study

J. T. Jensen, A. B. Edelman, B. A. Chen, D. F. Archer, K. T. Barnhart, M. A. Thomas, A. E. Burke, C. L. Westhoff, L. S. Wan, R. Sitruk-Ware, N. Kumar, B. Variano, D. L. Blithe

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Background: As part of a program to develop a novel estradiol-releasing contraceptive vaginal ring (CVR), we evaluated the pharmacokinetic (PK) profile of CVRs releasing segesterone acetate (Nestorone® (NES)) combined with one of three different estradiol (E 2 ) doses. Study design: A prospective, double-blind, randomized, multi-centered study to evaluate a 90-day CVR releasing NES [200 mcg/day] plus E 2 , either 10 mcg/day, 20 mcg/day, or 40 mcg/day in healthy reproductive-age women with regular cycles. Participants provided blood samples twice weekly for NES and E 2 levels during the first 60 days (ring 1) and the last 30 days (ring 2) of use. A subset underwent formal PK assessments at ring initiation, ring exchange (limited PK), and study completion. Results: The main study enrolled 197 women; 22 participated in the PK substudy. Baseline characteristics between the main and PK participants were comparable, with an average BMI of 25.8 kg/m 2 (SD 4.3). In the PK substudy, all three rings showed similar NES PK: mean area under the curve (AUC (0–72) ) 34,181 pg*day/mL; concentration maximum (C max ) 918 pg/mL; time to maximum concentration (T max ) 3.5 h. For E 2, the C max occurred at 2 h, and was significantly higher with the 20 mcg/day ring (mean 390 pg/mL); 10 mcg/day, 189 pg/mL, p=.003; 40 mcg/day, 189 pg/mL, p<.001), and declined rapidly to≤50 pg/mL for all doses by 24 h. For all subjects, the median E 2 levels remained under 35 pg/mL during treatment. Conclusion: PK parameters of NES were not affected when paired with different doses of E 2 , but E 2 levels from all three doses were lower than anticipated and no dose response was observed. Implications: While these novel estradiol-releasing combination contraceptive vaginal rings provided sustained release of contraceptive levels of Nestorone over 90 days, the E 2 levels achieved were not consistent with bone protection, and a dose–response was not observed.

Original languageEnglish (US)
Pages (from-to)422-427
Number of pages6
JournalContraception
Volume97
Issue number5
DOIs
StatePublished - May 2018

Keywords

  • Continuous cycling
  • Contraception
  • Contraceptive vaginal ring
  • Estradiol
  • Nestorone
  • Pharmacokinetics

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study'. Together they form a unique fingerprint.

  • Cite this

    Jensen, J. T., Edelman, A. B., Chen, B. A., Archer, D. F., Barnhart, K. T., Thomas, M. A., Burke, A. E., Westhoff, C. L., Wan, L. S., Sitruk-Ware, R., Kumar, N., Variano, B., & Blithe, D. L. (2018). Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study. Contraception, 97(5), 422-427. https://doi.org/10.1016/j.contraception.2018.01.012